Laboratory Of America Holdings Stock Earnings Reports

Labcorp reported a strong start to 2026: Q1 revenue was $3.5 billion, up 6% year-over-year, with adjusted EPS up ~11% and adjusted operating margin expanding >30 basis points to 14.4%. Organic growth was driven by Diagnostics (5% segment revenue growth; volumes +2.5%) and Biopharma Laboratory Services (BLS) (8% revenue growth; central labs up ~11% reported / ~5% organic constant currency). Trailing 12-month BLS book-to-bill remains healthy at 1.04 and BLS backlog is $8.6 billion. Management highlighted progress on M&A and hospital/regional lab partnerships (recent CHOP collaboration, completed Crouse Health assets, pending Parkview Health deal), continued expansion in specialty testing (oncology, neurology/Alzheimer’s, women’s health, autoimmune), and double-digit growth in Consumer Health (Labcorp OnDemand) with a May launch of the MyLabcorp app and AI features. Labcorp is deploying AI/robotics and partnerships (PathAI, AWS/Datavant, Optum.ai) under its LaunchPad initiatives to boost efficiency and customer experience. Cash was $981 million, total debt $6.3 billion; Q1 free cash flow was $71 million and full-year FCF guidance remains $1.24–1.36 billion. The company raised the midpoint of full-year revenue and EPS guidance and narrowed the EPS range: revenue growth guidance 5.0%–6.1% (includes FX tailwind), Diagnostics 5.1%–5.9%, BLS 3.8%–5.4%, and adjusted EPS guidance $17.70–$18.35 (midpoint ~10% growth). Key near-term risks and items to monitor include weather-related volume disruption (~$15M estimated Q1 impact), fuel cost sensitivity (estimated ~$5–$10M potential AOI impact), regulatory/payment policy uncertainty around PAMA/RESULTS Act and CMS CRUSH initiative, and reimbursement dynamics for certain specialty tests.